The validity of a new large study linking anticholinergic drugs to the risk of dementia has stirred up controversy.
FDA recalls insulin pumps due to cybersecurity miscommunication.
A new report from OptumRx reveals the top 4 drugs in development for the second quarter of 2019.
A women’s health organization is concerned about the safety and effectiveness of bremelanotide (Vyleesi) after FDA approved it to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.
The first FDA-approved device to reduce functional abdominal pain in younger patients with irritable bowel syndrome is now available to medical providers.
A record number of new oncology treatments launched in the US last year and spending on cancer drugs soared. Here are the top 6 cancer drug trends revealed in the report.
FDA cleared the first-and-only calcitonin gene-related peptide (CGRP) antibody for cluster headaches.
The first respiratory biologic to be approved for administration via an autoinjector will be available in the US soon.
FDA granted market authorization for a non-invasive, smartphone device that offers respite from migraines.
FDA cleared alpelisib (Piqray), the first PI3K inhibitor to treat breast cancer, to be used in combination with fulvestrant (Faslodex).